Study Stopped
Study was not submitted or reviewed by the NSH REB, reason unknown
Genetic Identification (ID) of Segmental Dysplastic Nevi
Identification of the Genetic Mutation Responsible for Segmental Dysplastic Nevi
1 other identifier
observational
N/A
1 country
1
Brief Summary
The investigators' goal is to identify the mutation in the gene that is responsible for the development of segmental dysplastic nevi. To identify the gene the investigators may use a candidate gene approach (i.e. sequence specific genes that are thought to be involved: NRAS, BRAF, etc) or a genome-wide approach trying to implicate regions in the genome (Loss-of-heterozygosity or copy number changes on comparative genomic hybridization).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Aug 2009
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2009
CompletedFirst Submitted
Initial submission to the registry
August 7, 2009
CompletedFirst Posted
Study publicly available on registry
August 10, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedAugust 21, 2024
September 1, 2009
4 months
August 7, 2009
August 19, 2024
Conditions
Study Arms (1)
Segmental Dysplastic Nevi
One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
Interventions
Eligibility Criteria
One patient who is already known to the principal investigator
You may qualify if:
- Patient with a positive history of segmental dysplastic nevi
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Capital Heatlh
Halifax, Nova Scotia, B3H1V7, Canada
Biospecimen
The participant will be involved in the study for the length of time required to obtain 5 to 6 skin biopsiesThe laboratory testing that will be performed includes a genetic analysis of the tissue obtained from biopsy. The genetic analysis will take place in the genetics lab of Dr. Hensin Tsao, Massachusetts General Hospital, Bartlett 622, 48 Blossom Street, Boston MA, 02114.
Study Officials
- PRINCIPAL INVESTIGATOR
Richard GB Langley, MD, FRCPC
Capital Health/Dalhousie University
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 7, 2009
First Posted
August 10, 2009
Study Start
August 1, 2009
Primary Completion
December 1, 2009
Study Completion
March 1, 2010
Last Updated
August 21, 2024
Record last verified: 2009-09